Emmessar Biotech

Why is Emmessar Biotech & Nutrition Ltd falling/rising?

As of 24-Aug, Emmessar Biotech & Nutrition Ltd's stock price is at 23.92, unchanged from the previous session, and has seen an 18.50% year-to-date decline. The stock is underperforming compared to the Sensex and shows bearish sentiment, indicated by trading below moving averages and decreased investor participation.

As of 24-Aug, Emmessar Biotech & Nutrition Ltd's stock price is currently at 23.92, showing no change from the previous trading session. The stock's performance over various periods indicates a downward trend, with a year-to-date decline of 18.50% compared to a 9.21% drop in the benchmark Sensex. Over the past month, the stock has decreased by 2.17%, while the Sensex has increased by 1.72%.<BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish sentiment among investors. There has also been a notable decline in investor participation, with delivery volume on August 21 falling by 26.06% compared to the 5-day average. This decrease in trading activity further indicates a lack of confidence in the stock, contributing to its current price stagnation. Overall, these factors suggest that Emmessar Biotech & Nutrition Ltd is experiencing a decline in interest and performance in the market.

Which are the latest news on Emmessar Biotech?

Who are in the management team of Emmessar Biotech?

The management team of Emmessar Biotech includes MSR Ayyangar (Chairman & Managing Director), Anuradha Raghavan, Sarada Raghavan, Rajalakshmi Srinivasa Raghavan (all Non Executive Directors), Anantharama Sethmani Subramanian, Milind S Desai (Independent Directors), Jayavel Balaiah Nadar (Executive Director & CFO), and Priyanka Omprakash Sharma (Company Secretary & Compliance Officer). This team offers a diverse range of expertise.

The management team of Emmessar Biotech includes the following individuals:<BR><BR>1. **MSR Ayyangar** - Chairman & Managing Director<BR>2. **Anuradha Raghavan** - Non Executive Director<BR>3. **Sarada Raghavan** - Non Executive Director<BR>4. **Anantharama Sethmani Subramanian** - Independent Director<BR>5. **Jayavel Balaiah Nadar** - Executive Director & CFO<BR>6. **Rajalakshmi Srinivasa Raghavan** - Non Executive Director<BR>7. **Priyanka Omprakash Sharma** - Company Secretary & Compliance Officer<BR>8. **Milind S Desai** - Independent Director<BR><BR>This team brings a diverse range of expertise to the company.

What does Emmessar Biotech do?

Emmessar Biotech & Nutrition Ltd manufactures super specialty fine chemicals and was established in 1992. As of June 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 13 Cr.

Overview:<BR>Emmessar Biotech & Nutrition Ltd operates in the commodity chemicals industry, focusing on the manufacturing of super specialty fine chemicals.<BR><BR>History:<BR>The company was originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL). It has developed many specialty fine chemicals and gained official recognition for its R&D from the DSIR, Ministry of Science & Technology, Government of India, in early 1996. The latest quarterly results reported net sales and net profit of 0 Cr for June 2026.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap value: INR 13 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 44<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.90<BR>- Return on Equity: 4.80%<BR>- Price to Book: 1.45<BR><BR>Contact Details:<BR>- Address: Plot No T-3/2 MIDC Area, P O Box No 39 Taloja Raigad Maharashtra : 410208<BR>- Tel: 91-022-20870587<BR>- Email: investors@ebnl.co.in/emmessar@vsnl.<BR>- Website: http://www.ebnl.co.in

Who are the peers of the Emmessar Biotech?

Emmessar Biotech's peers include Square Four Pro., Advance Petroch., Omkar Pharmachem, Kobo Biotech, and others. In terms of management risk and growth, Sreechem Resins shows excellent management risk, while Emmessar Biotech has below-average growth; Kobo Biotech leads in 1-year returns at 111.76%, while Emmessar Biotech's return is -11.88%.

Peers: The peers of Emmessar Biotech are Square Four Pro., Advance Petroch., Omkar Pharmachem, Kobo Biotech, Link Pharma Chem, Kuwer Industries, Sreechem Resins, Lime Chemicals, Bhagawati Oxygen, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Advance Petroch. Below Average management risk is noted at Link Pharma Chem, Kuwer Industries, and Lime Chemicals, and the rest. Growth is rated as Good for Advance Petroch, Average for Padmanabh Inds., Below Average for Emmessar Biotech, Link Pharma Chem, Kuwer Industries, Sreechem Resins, and Lime Chemicals, and the rest. Management risk does not qualify for Square Four Pro., Omkar Pharmachem, Kobo Biotech, and Bhagawati Oxygen.<BR><BR>Return Snapshot: Kobo Biotech has the highest 1-year return at 111.76%, while Square Four Pro. has the lowest at -15.30%. Emmessar Biotech's 1-year return of -11.88% is better than Square Four Pro. but worse than Kobo Biotech. Additionally, Sreechem Resins and Bhagawati Oxygen have negative six-month returns.

How big is Emmessar Biotech?

As of 14th August, Emmessar Biotech & Nutrition Ltd has a market capitalization of 12.00 Cr, with recent net sales of 0.33 Cr and net profit of 0.39 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Emmessar Biotech & Nutrition Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 0.33 Cr, while the sum of Net Profit for the same period is 0.39 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 7.71 Cr, and Total Assets amount to 9.22 Cr.

When is the next results date for Emmessar Biotech & Nutrition Ltd?

The next results date for Emmessar Biotech & Nutrition Ltd is August 7, 2026.

The next results date for Emmessar Biotech & Nutrition Ltd is scheduled for August 7, 2026.

How has been the historical performance of Emmessar Biotech?

Emmessar Biotech has experienced significant fluctuations in financial performance, with net sales and operating income peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25, while operating profit turned negative and total assets and liabilities increased. The company has shown a consistent zero balance in cash and cash equivalents, indicating poor cash flow.

Answer:<BR>The historical performance of Emmessar Biotech shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Emmessar Biotech's net sales have varied considerably, peaking at 6.99 Cr in Mar'21 before declining to 0.61 Cr in Mar'25. The total operating income followed a similar trend, with a high of 6.99 Cr in Mar'21 and a drop to 0.61 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 6.14 Cr in Mar'21 and decreasing to 1.56 Cr in Mar'25. Operating profit (PBDIT) has been negative in recent years, with a loss of 0.95 Cr in Mar'25, contrasting with a profit of 0.85 Cr in Mar'21. Profit after tax has decreased from 1.45 Cr in Mar'21 to 0.32 Cr in Mar'25. The company's total assets have increased from 5.19 Cr in Mar'20 to 9.22 Cr in Mar'25, while total liabilities have also risen from 5.19 Cr to 9.22 Cr in the same period. Cash and cash equivalents have shown a consistent zero balance from Mar'20 to Mar'25, indicating a lack of cash flow from operations. Overall, Emmessar Biotech has experienced a decline in sales and profitability, alongside an increase in total assets and liabilities.

Who are the top shareholders of the Emmessar Biotech?

The top shareholders of Emmessar Biotech include Emmessar Technologies Limited with 21.79%, individual investors with 37.15%, and Sandeep Rao as the highest public shareholder at 2.04%. There are no foreign institutional investors, and no promoter holdings are pledged.

The top shareholders of Emmessar Biotech include the promoters, with Emmessar Technologies Limited holding the largest stake at 21.79%. Additionally, individual investors collectively own 37.15% of the company. The highest public shareholder is Sandeep Rao, who holds 2.04%. There are also two mutual fund schemes that hold a very small percentage of shares (0.05%), and currently, there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

Is Emmessar Biotech overvalued or undervalued?

As of April 25, 2023, Emmessar Biotech is rated as risky and overvalued, with a PE ratio of 16.32, a Price to Book Value of 2.12, a troubling ROCE of -104%, and has underperformed the Sensex by declining 26.44% year-to-date.

As of 25 April 2023, the valuation grade for Emmessar Biotech has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial stability. The company is currently assessed as overvalued. Key ratios include a PE ratio of 16.32, a Price to Book Value of 2.12, and a troubling ROCE of -104.00%. <BR><BR>In comparison to its peers, Emmessar Biotech's PE ratio is significantly lower than that of Solar Industries, which stands at 123.77, and Godrej Industries at 46.63, both of which are considered very expensive. The negative EV to EBIT and EV to EBITDA ratios of -9.07 and -9.44, respectively, further highlight the company's financial challenges. Notably, Emmessar's stock has underperformed relative to the Sensex, particularly year-to-date, where it has declined by 26.44% compared to the Sensex's gain of 5.61%.

What is the technical trend for Emmessar Biotech?

As of May 30, 2025, Emmessar Biotech's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

As of 30 May 2025, the technical trend for Emmessar Biotech has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish. The Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but mildly bearish monthly. Dow Theory reflects a mildly bearish trend weekly, contrasting with a mildly bullish stance monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish indicators on the weekly MACD and KST.

Has Emmessar Biotech declared dividend?

No Dividend History Available